SEATTLE, Sept. 25, 2017 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the Global Myelodysplastic Syndrome Treatment Market (By drug - Azacitidine, Lenalidomide, Dacogen, Jadenu) was valued at US$ 2,411.4 million in 2016 and is projected to witness a CAGR of 12.7% over the forecast period (2017-2025) . Growing incidence of the bone marrow disorders and cytogenetic abnormalities expected to be the major factor driving growth of the global myelodysplastic syndrome treatment market over the foreseeable future.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market...market-775
Key Trends and Analysis of the Myelodysplastic Syndrome Treatment Market: According to a report published in 2015 by American Cancer Society, myelodysplastic syndromes occurs at the rate of 4.8 cases per 100,000 people, which counts up to 13,000 new cases of MDS in the U.S. every year. The report also states that this number has witnessed an increase in the last few years as the average population is ageing every consecutive year. Moreover, the fact report 2014-2015 published by Leukemia and Lymphoma Society suggests that the overall incidence of MDS in the U.S. by gender are 6.7 per 100,000 in male while 3.8 per 100,000 in females.
Request Sample Copy of the Business Report
Few pipeline drugs include Durvalumab (PD-L1 Inhibitor), and Luspatercept which are currently (as of 2016) in phase 2 trials. Positive outcomes from the clinical trials of many such molecules in pipeline would drive the revenues in global MDS market. Furthermore, in 2016, Opsona Therapeutics Ltd. received orphan drug designation for its OPN-305 humanized IgG4 monoclonal antibody for MDS treatment. Also, after Celgene lost its U.S. exclusivity for Vidaza, many generic formulations have entered in the market for Vidaza and Natco Pharma is also expected to launch generic version of Vidaza in 2017, which will further boost myelodysplastic syndrome treatment market.
Key Market Takeaways:
- The global myelodysplastic syndrome treatment market is expected to expand at a CAGR of 12.7% during the forecast period (2016–2025), as there exists a huge potential market, especially in Asia Pacific, Latin America, Middle East, and Africa
- Robust development in drug therapies, drugs showing potential in pipeline and inclusion of generic versions of the branded products in the market due to patent expiries are expected to drive the global myelodysplastic syndrome market
- Some of the major players involved in the global myelodysplastic syndrome treatment market are Celgene Corporation, Novartis AG and Otsuka, Astellas, Astex, Acceleron Pharma, Onconova Pharmaceuticals, GlaxoSmithKline Plc, Pfizer, Inc., Eli-Lilly and CTI Biopharma
Contact Us:
Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
